Underdog Pharmaceuticals
Underdog develops interventions targeting toxic forms of cholesterol to provide true disease-modifying treatments for age-related diseases.
Funding reportedLast round: Seed
What company datasets say Underdog Pharmaceuticals raised
Funding, as reported
Reported in all17.5Min the source's currency
Rounds3
Last roundSeed
Last round dateSept 2021
Investors listed4
Founders and team
From Underdog Pharmaceuticals's own website: 1 founder, 9 on the team.
Dr. Keivan SadrerafiDirector of Scientific Computing & Co-Founder
- Dr. Noah RosenbergVice President of Pharmaceutical Development & CMC
- Michael KopeCEO of Corporate Affairs / Director
- Dr. Daniel M. ClemensHead of Clinical Affairs
- Ana SilbergSenior Research Associate
- Bill LiaoChairman of the Board
- Darren DinhSenior Research Associate
- Dr. Amelia AndersonPrincipal Scientist
- Dr. Prerna BhargavaAssociate Scientist / Lab Manager
- Noa PetlerSenior Research Associate
On a portfolio page
Investors who name them
Each firm lists Underdog Pharmaceuticals on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
Pharmaceutical in the same market
Startups like it
Is this your company?
Add your raise, your deck and your story, and put Underdog Pharmaceuticals in front of investors. Or tell us what we have wrong.